Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study
<h4>Objectives</h4> Our study aims at comparing the efficacy and safety of IFN-based therapy (lopinavir/ritonavir, ribavirin, and interferon β-1b) vs. favipiravir (FPV) in a cohort of hospitalized patients with non-critical COVID-19. <h4>Methods</h4> Single center observation...
Main Authors: | Areej A. Malhani, Mushira A. Enani, Fatemeh Saheb Sharif-Askari, Mona R. Alghareeb, Roaa T. Bin-Brikan, Safar A. AlShahrani, Rabih Halwani, Imad M. Tleyjeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191942/?tool=EBI |
Similar Items
-
Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
by: Areej A Malhani, et al.
Published: (2021-01-01) -
Comparison of non-severe COVID-19 pneumonia patients treated with lopinavir/ritonavir and favipiravir
by: Bengü Şaylan, et al.
Published: (2020-11-01) -
Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
by: B. K. Romanov
Published: (2020-09-01) -
Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
by: Yan-Ming Zeng, et al.
Published: (2020-05-01) -
Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
by: Manoon Surabotsophon, et al.
Published: (2020-12-01)